Longboard Pharmaceuticals, Inc. - Common Stock (LBPH)
59.98
0.00 (0.00%)
Longboard Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies to address the needs of patients with neurological disorders
The company specializes in the research and development of cannabinoid-based medications, leveraging its proprietary technology to create novel treatments aimed at improving the quality of life for individuals suffering from conditions such as epilepsy and other related ailments. Longboard is dedicated to advancing its clinical programs and fostering collaborations within the medical and scientific communities to bring new hope to patients in need.
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankruptbenzinga.com
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.
Via Benzinga · December 7, 2024
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lagsbenzinga.com
S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.
Via Benzinga · October 21, 2024
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?benzinga.com
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
Via Benzinga · October 20, 2024
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jumpbenzinga.com
Via Benzinga · October 14, 2024
Looking Into Longboard Pharmaceuticals's Recent Short Interestbenzinga.com
Via Benzinga · January 19, 2024
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 14, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · October 14, 2024
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Recordinvestors.com
Lundbeck will buy Longboard Pharmaceuticals in a deal slated to close in the fourth quarter.
Via Investor's Business Daily · October 14, 2024
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?benzinga.com
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological conditions.
Via Benzinga · October 14, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 14, 2024
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 14, 2024
Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · September 18, 2024
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coveragebenzinga.com
Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets.
Via Benzinga · September 10, 2024
3 Russell 2000 Growth Stocks That Could Be Worth the Riskfool.com
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
Via The Motley Fool · July 23, 2024
LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024investorplace.com
LBPH stock results show that Longboard Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 2, 2024
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Shares of Intel Corporation (NASDAQINTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
Via Benzinga · January 26, 2024
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higherfool.com
You might say that this biotech stock is magnificent.
Via The Motley Fool · January 17, 2024
Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Knowbenzinga.com
Via Benzinga · January 16, 2024
Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnaybenzinga.com
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Equitrans Midstream Corporation (NYSEETRN) is very solid. "Good growth, good yield.
Via Benzinga · January 4, 2024
Why Longboard Pharmaceuticals Stock Is Fallingbenzinga.com
Longboard Pharmaceuticals Inc (NASDAQLBPH) shares are trading lower by 11.3% to $22.26 Wednesday afternoon after the company announced that it commenced a $150 million underwritten public offering and expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of s
Via Benzinga · January 3, 2024
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Todaybenzinga.com
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy NASDAQ faced a downturn, falling 1.63% to 14,765.94. Similarly, the S&P 500 also witnessed a decline, dropping 0.57% to 4,742.83.
Via Benzinga · January 2, 2024
Why Longboard Pharma Catapulted 316%, Leading A Biotech Stock Rallyinvestors.com
Longboard Pharmaceuticals is working on treatments for seizure disorders.
Via Investor's Business Daily · January 2, 2024
Crude Oil Down 2%; Tesla Deliveries Top Estimatesbenzinga.com
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to 14,743.80. The S&P 500 also fell, dropping, 0.66% to 4,738.37.
Via Benzinga · January 2, 2024